A Phase 2 Study of Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone (LR-CD) for Untreated Low-Grade Non-Hodgkin Lymphoma Requiring Therapy
American Journal of Hematology - United States
doi 10.1002/ajh.24693
Full Text
Open PDFAbstract
Available in full text
Categories
Date
March 22, 2017
Authors
Publisher
Wiley